Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature

Published:2023-10-26 Issue:11 Volume:11 Page:2903
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Proietti Ilaria¹,Filippi Luca²^ORCID,Tolino Ersilia¹,Bernardini Nicoletta¹,Svara Francesca¹,Trovato Federica¹,Di Cristofano Claudio³^ORCID,Petrozza Vincenzo³^ORCID,Bagni Oreste⁴,Vizzaccaro Andrea¹,Skroza Nevena¹^ORCID,Potenza Concetta¹

Affiliation:

1. Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy

2. Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospitale, Viale Oxfors 81, 00133 Rome, Italy

3. Pathology Unit, Department of Medical-Surgical Sciences and Biotechnologies, ICOT Hospital, Sapienza University of Rome, 04100 Latina, Italy

4. Department of Nuclear Medicine, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, Italy

Abstract

Basal cell carcinoma (BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. Basosquamous Carcinoma (BSC) represents an aggressive histological subtype of BCC with intermediate features between Squamous Cell Carcinoma (SCC) and BCC. Cemiplimab is currently approved as first-line therapy in SCC and second-line therapy in BCC patients who have progressed on or are intolerant of a Hedgehog pathway Inhibitor (HHI). Our study describes the case of a 59-year-old man with BSC who was successfully treated with 5 cycles of Cemiplimab as first-line therapy and Sonidegib as second-line therapy. Currently, the efficacy of Cemiplimab against BSC and other histopathological subtypes of BCC has not been fully elucidated, as has the role of sequential or combination therapy with Cemiplimab and HHI in the management of BSC. The aim of this case report is to highlight the need to outline the use of checkpoint inhibitors in BCCs and focus attention on the synergistic role of Cemiplimab and HHIs in such a controversial entity as BSC.

Funder

Sun Pharmaceutilca industries, Inc.

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Link

https://www.mdpi.com/2227-9059/11/11/2903/pdf

Reference45 articles.

1. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial;Stratigos;Lancet Oncol.,2021

2. (2023, June 15). Guidelines CUTANEUS TUMORS NOT MELANOMA Basal Cell Carcinoma; AIOM 2021. Available online: https://www.iss.it/documents/20126/8403839/LG-AIOM-313.

3. Update in the Management of Basal Cell Carcinoma;Herms;Acta Derm. Venereol.,2020

4. McDaniel, B., Badri, T., and Steele, R.B. (2023). StatPearls, StatPearls Publishing.

5. Dika, E., Scarfì, F., Ferracin, M., Broseghini, E., Marcelli, E., Bortolani, B., Campione, E., Riefolo, M., Ricci, C., and Lambertini, M. (2020). Basal Cell Carcinoma: A Comprehensive Review. Int. J. Mol. Sci., 21.